Jeffrey Statland, M.D.
Jeff Statland, M.D., is a professor of neurology at the University of Kansas Medical Center and a leading researcher in the field of facioscapulohumeral muscular dystrophy (FSHD). He is the co-principal investigator for ReSolve (Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD), an ongoing observational study that aims to validate new clinical outcome assessments and evaluate physiological biomarkers to support the design and implementation of future clinical trials. In addition to co-leading the ReSolve natural history study, Dr. Statland, along with his collaborators at the University of Rochester Medical Center, is developing a disease-specific patient reported health inventory and molecular and neuroimaging biomarkers of disease activity for future FSHD clinical trials.
Dr. Statland holds a B.A. from Sarah Lawrence College, a MFA from Emerson College and a medical degree from the University of Kansas School of Medicine. He completed residency training in the department of neurology at the University of Kansas Medical Center and also conducted a fellowship in experimental therapeutics of neurologic disorders in the department of neurology at the University of Rochester Medical Center. He is board certified by the American Board of Psychiatry and Neurology.
To learn more, visit Dr. Statland's University of Kansas Health System bio.